CD274 and non-small cell lung carcinoma: The PACIFIC trial showed an unprecedented 5-year overall survival (OS) of 42.9% for unresectable non-small cell lung cancer (NSCLC) treated with definitive chemoradiation and adjuvant durvalumab, a PD-L1 inhibitor (1–3).